| 货号 | 25800S |
| 反应种属 | Human |
| 来源宿主 | Rabbit |
| 应用 | WB,IP |
| 目标/特异性 | MAGE-A3 Antibody recognizes endogenous levels of total MAGE-A3 protein. This antibody cross-reacts with MAGE-A6. |
| 使用方法 | Western Blotting (1:1000) Immunoprecipitation (1:50) |
| 供应商 | CST |
| 灵敏度 | Endogenous |
| 背景 | Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3). Melanoma antigen-A3 (MAGE-A3) is a cancer testis antigen and belongs to the type I MAGE family of proteins. The expression of MAGE-A3 is normally restricted to the human testis but is aberrantly upregulated in a number of human cancers, such as lung cancer, colorectal cancer, and multiple myeloma (4-6). Research studies have recently demonstrated that MAGE-A3 drives tumorigenesis as part of the MAGE-A3-TRIM28 ubiquitin ligase complex that promotes proteasomal degradation of the tumor suppressor kinase AMPK (7). Due to its upregulated and selective expression in human tumors and high degree of immunogenicity, MAGE-A3 has received significant attention as a novel immunotherapy target through the use of vaccines and adoptive cell therapy (8,9). |
| 存放说明 | -20C |
| 计算分子量 | 45 |
| 参考文献 | 1 . Caballero, O.L. and Chen, Y.T. (2009) Cancer Sci 100, 2014-21. 2 . De Smet, C. et al. (1999) Mol Cell Biol 19, 7327-35. 3 . Gjerstorff, M.F. et al. (2015) Oncotarget 6, 15772-87. 4 . Jang, S.J. et al. (2001) Cancer Res 61, 7959-63. 5 . Shantha Kumara, H.M. et al. (2012) Cancer Immun 12, 16. 6 . Atanackovic, D. et al. (2007) Blood 109, 1103-12. 7 . Pineda, C.T. et al. (2015) Cell 160, 715-28. 8 . Straetemans, T. et al. (2012) Clin Dev Immunol 2012, 586314. 9 . Esfandiary, A. and Ghafouri-Fard, S. (2015) Immunotherapy 7, 683-704. |
Western blot analysis of extracts from various cell lines using MAGE-A3 Antibody (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). As expected, MAGE-A3 protein expression is not detected in HCC1143 cells. | |
Western blot anlysis of extracts from 293T cells, mock transfected (-) or transfected with constructs expressing Myc/DDK-tagged full-length human MAGE-A3 protein (hMAGE-A3-Myc/DDK; +) and Myc/DDK-tagged full-length human MAGE-A6 protein (hMAGE-A6-Myc/DDK; +), using MAGE-A3 Antibody (upper), DYKDDDDK Tag Antibody #2368 (middle), and β-Actin (D6A8) Rabbit mAb #8457 (lower). | |
Immunoprecipitation of MAGE-A3 from SK-MEL-28 cell extracts. Lane 1 is 10% input, lane 2 is Normal Rabbit IgG #2729, and lane 3 is MAGE-A3 Antibody. Anti-Rabbit HRP-conjugated light-chain-specific secondary antibody was used for detection. Western blot analysis was performed using MAGE-A3 Antibody. |
